Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
About Zymeworks Inc. (Nasdaq: ZYME)
Zymeworks Inc. is a global clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Headquartered in Vancouver, British Columbia, Zymeworks leverages its proprietary therapeutic platforms, including Azymetric™ and EFECT™, to engineer highly differentiated antibody-based therapeutics for difficult-to-treat diseases such as cancer, autoimmune disorders, and inflammatory conditions. The company’s mission is to make a meaningful impact on patients’ lives by addressing significant unmet medical needs through innovative solutions.
Core Business and Therapeutic Platforms
Zymeworks’ business model centers on its proprietary platforms, which enable the precise engineering of bispecific and trispecific antibodies and antibody-drug conjugates (ADCs). The Azymetric™ platform allows the development of multifunctional antibodies capable of binding to multiple targets, unlocking unique mechanisms of action. The EFECT™ platform enhances immune modulation, enabling the creation of therapies with improved efficacy and safety profiles. Together, these platforms provide a robust foundation for developing next-generation therapeutics targeting oncology, autoimmune diseases, and inflammation.
Pipeline and Key Product Candidates
Zymeworks has built a diversified pipeline of clinical and preclinical candidates aimed at addressing challenging diseases:
- Ziihera® (zanidatamab-hrii): A bispecific HER2-targeted antibody developed using the Azymetric™ platform, Ziihera® received accelerated FDA approval for the treatment of HER2-positive biliary tract cancer (BTC). It is the first dual HER2-targeted therapy approved for this indication in the U.S.
- ZW171: A bispecific T-cell engager targeting mesothelin (MSLN) and CD3, designed to treat MSLN-expressing cancers such as ovarian cancer and non-small cell lung cancer (NSCLC).
- ZW191: An antibody-drug conjugate targeting folate receptor-alpha (FR⍺) in ovarian, endometrial, and NSCLC cancers, incorporating a proprietary topoisomerase I inhibitor payload.
- ZW220 and ZW251: ADCs targeting NaPi2b and glypican-3 (GPC3), respectively, with potential applications in ovarian, NSCLC, and hepatocellular carcinoma.
Strategic Collaborations and Revenue Model
Zymeworks has established strategic partnerships with leading biopharmaceutical companies, including Jazz Pharmaceuticals, BeiGene, and GSK. These collaborations provide the company with significant milestone payments, royalties, and co-development opportunities. For example, Zymeworks is eligible to receive up to $1.1 billion in milestone payments under its agreement with GSK and up to $1.4 billion in combined regulatory and commercial milestones from Jazz Pharmaceuticals for zanidatamab. These partnerships enhance the company’s ability to advance its pipeline while sharing development costs and risks.
Competitive Position and Market Significance
Operating in the highly competitive biopharmaceutical sector, Zymeworks differentiates itself through its proprietary platforms and focus on multifunctional biotherapeutics. Its FDA-approved Ziihera® and robust pipeline underscore its leadership in developing innovative therapies for HER2-expressing and other challenging cancers. The company’s expertise in protein engineering and strategic collaborations position it as a key player in the global biotechnology landscape.
Commitment to Innovation
Zymeworks continues to expand its pipeline with an emphasis on solid tumors, hematological cancers, and autoimmune diseases. Its disciplined R&D strategy, supported by a strong financial position, enables the company to advance multiple candidates into clinical development. With a focus on addressing complex diseases, Zymeworks aims to redefine therapeutic paradigms and deliver transformative solutions to patients worldwide.
Zymeworks Inc. (Nasdaq: ZYME) presented new data from its clinical and preclinical programs at the 2023 American Association for Cancer Research Annual Meeting. Key highlights include:
- ZW191 showed strong responses in FRα-low expressing patient-derived xenograft models, with positive pharmacokinetic and safety profiles.
- ZW171 effectively killed cancer cells while mitigating risks of toxicity and adverse immune activation.
- ZW251 demonstrated significant anti-tumor activity in various glypican-3-expressing cancer models.
The company aims to advance at least five novel therapeutics into clinical studies by 2027, bolstered by their innovative antibody-drug conjugates and multispecific antibody platforms.
Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company focused on developing innovative biotherapeutics, will report its Q1 2023 financial results on May 8, 2023, after market close. Following this announcement, Zymeworks will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Investors can access the live event and recordings through Zymeworks’ website.
Founded with a mission to address challenging cancers and other serious diseases, Zymeworks specializes in antibody-based therapies using its proprietary Azymetric™ technology. The company is advancing its lead candidate, zanidatamab, and next-generation product zanidatamab zovodotin (ZW49), both targeting HER2-expressing cancers.
Zymeworks Inc. (Nasdaq: ZYME) announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Miller brings over 25 years of experience in oncology and corporate development. His expertise is expected to support Zymeworks in its collaboration efforts with Jazz Pharmaceuticals and BeiGene on zanidatamab, a bispecific antibody currently undergoing multiple clinical trials. Kenneth Galbraith, CEO, emphasized Miller's strategic insights will enhance the company's pipeline of drug candidates. Miller's previous roles include leadership positions at Aro Biotherapeutics and Celator Pharmaceuticals, where he contributed to significant collaborations and business strategies that generated substantial revenues. Zymeworks focuses on developing innovative biotherapeutics aimed at improving outcomes for patients with difficult-to-treat cancers.
Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology firm, will participate in two upcoming investor conferences. Management will hold one-on-one meetings and present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25 in
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced eleven abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting from April 14-19, 2023, in Orlando, FL. The abstracts will showcase advancements in the company’s antibody drug conjugates, multispecific antibodies, and clinical candidates, including ZW171 and ZW191. The management team will host a conference call on April 18, 2023, at 6:30 pm EST to discuss these developments. The abstracts reflect Zymeworks' commitment to pioneering treatments for difficult-to-treat cancers.
Zymeworks Inc. (ZYME) reported a significant turnaround in 2022, achieving $412.5 million in total revenue, a sharp increase from $26.7 million in 2021. The company posted a net income of $124.3 million ($1.90 per share) compared to a net loss of $211.8 million in the previous year. Cash resources stand at $492.2 million, ensuring a runway through 2026. Key developments include positive Phase 2 study results for zanidatamab and a substantial licensing agreement with Jazz Pharmaceuticals, potentially worth up to $1.76 billion. Zymeworks aims to advance multiple clinical studies and develop five novel product candidates over the next five years.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. The management will attend the Barclays Global Healthcare Conference on March 14-15, presenting on March 14 at 10:45 am EST in Miami Beach, FL. Additionally, the team will join the Cantor: The Future of Oncology Virtual Symposium on April 3-4 for virtual meetings and a fireside chat. Presentations and webcasts will be accessible on Zymeworks’ website.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
What does Zymeworks specialize in?
What is Ziihera® (zanidatamab-hrii)?
What are Zymeworks’ proprietary platforms?
Who are Zymeworks’ key collaborators?
What is the focus of Zymeworks’ pipeline?
